Scarica l'app Stockscreener
20.90
0.05%
0.010
Dopo l'orario di chiusura:
20.90
Immunome Inc Borsa (IMNM) Ultime notizie
IMNM Initiated Coverage by Stifel -- Rated Hold with PT at $24.0 - GuruFocus
Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues - Yahoo Finance
Immunome gains FDA IND clearance for IM‑1340 solid tumour study - Mugglehead Investment Magazine
Stifel initiates Immunome stock coverage with Hold rating at $24 By Investing.com - Investing.com Nigeria
Immunome, Inc. (IMNM) stock price, news, quote and history - uk.finance.yahoo.com
Immunome (IMNM) Gains FDA IND Clearance for IM-1340 Targeting Ad - GuruFocus
Immunome receives FDA clearance for IM-1340 solid tumor trial - Investing.com
Immunome receives FDA clearance for IM-1340 solid tumor trial By Investing.com - Investing.com South Africa
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Business Wire
(IMNM) Risk Channels and Responsive Allocation - Stock Traders Daily
A. G. P. Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $32 - Moomoo
IMNM Initiates Coverage On Alliance Global Partners -- Rating Se - GuruFocus
Immunome Inc. (IMNM) Edges Higher to $23.97 as Traders Eye $25.17 ResistanceQuality ETF - siam.in
Immunome stock gains as analyst targets highlight upside potential - AD HOC NEWS
Immunome Stock Price Forecast. Should You Buy IMNM? - StockInvest.us
Immunome, Inc. (IMNM) Stock Analysis: Exploring a 51.72% Potential Upside in Biotechnology - DirectorsTalk Interviews
Immunome CSO Higgins Jack Executes 18,000 Options at $1.35, Sells and Gifts Shares (NASDAQ: IMNM) - Kalkine Media
Immunome Inc. (IMNM) Edges Up 2.51% to $24.55 as Buyers Hold Above Key SupportPCR Spike - careplusvn.com
Liquidity Mapping Around (IMNM) Price Events - Stock Traders Daily
Planned sale of 13,200 Immunome (NASDAQ: IMNM) shares disclosed in Rule 144 notice - stocktitan.net
IMNM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
IMNM Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesEarnings Miss Alert - dars.gov.et
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome, Inc. Revenue Breakdown – NASDAQ:IMNM - TradingView
Immunome Inc (NASDAQ: IMNM) Share Price, IMNM Stock News, IMNM Share Price & Updates - kalkine.ca
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Immunome (NASDAQ:IMNM) Is In A Good Position To Deliver On Growth Plans - Moomoo
(IMNM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunome (IMNM) Reports A Wider Loss, Is The Premium Valuation Justified? - Sahm
Immunome (IMNM) Update: Closes 0.98% Lower at $28.24 at the Close; Chart Watch: Traders Can Monitor the $26.83-$29.65 Range in the Current UpdateCommon Gap - siam.in
Immunome (IMNM) Results Review: EPS Clears the Reported Estimate for the Current Session; Closing Move - dars.gov.et
Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors? - Sahm
Immunome (IMNM) Financial Update: EPS Beats Its Estimate in the Latest Session; Investor Response: Shares Close 1.57% Higher for the Current SessionProduct Revenue Analysis - careplusvn.com
Enterprise value to revenue forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Bank of America Corp DE Boosts Stake in Immunome, Inc. $IMNM - MarketBeat
IMNM|Immunome Inc|Price:28.520|Chg%:+0.440 - TradingKey
Enterprise value to EBIT forward of Immunome, Inc. – NASDAQ:IMNM - TradingView
Immunome (NASDAQ:IMNM) Sets New 12-Month HighShould You Buy? - MarketBeat
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration - Sahm
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
IMNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline at Pre-Revenue Oncology BiotechBuyback Announcement Report - vinanet.vn
Is Immunome’s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story? - Sahm
Immunome director Isaac Barchas sells $940,453 in common stock - Investing.com
Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM - MarketBeat
Immunome (IMNM) Is Up 8.7% After Wider Loss And ESOP Shelf Filing What’s Changed - simplywall.st
Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Immunome (IMNM) Q1 2026 Earnings: Narrower-than-Expected Loss Drives 2.95% Stock GainRevenue Miss Report - vinanet.vn
IMNM Q1 2026 Earnings: Narrower Net Loss Beats on Cost ControlPerformance Review - vinanet.vn
T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5% - Stock Titan
Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A - Stock Titan
HC Wainwright Issues Negative Forecast for Immunome Earnings - MarketBeat
Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon (IMNM) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Immunome (IMNM) - The Globe and Mail
Renaissance Technologies LLC Makes New Investment in Immunome, Inc. $IMNM - MarketBeat
Immunome gets FDA nod for varegacestat NDA, sets PDUFA date for April 2027 - Pluang
Immunome (NASDAQ:IMNM) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells 11,048 Shares - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $1,633,892.93 in Stock - MarketBeat
Immunome director Isaac Barchas sells over $2.1m in shares By Investing.com - Investing.com South Africa
Immunome director Isaac Barchas sells over $2.1m in shares - Investing.com
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):